ID: ALA610046

Max Phase: Preclinical

Molecular Formula: C27H29NO4

Molecular Weight: 431.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1[C@@H](Cc2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5

Standard InChI:  InChI=1S/C27H29NO4/c29-20-9-8-18-13-21-27(31)14-19(12-16-4-2-1-3-5-16)23(30)25-26(27,22(18)24(20)32-25)10-11-28(21)15-17-6-7-17/h1-5,8-9,17,19,21,25,29,31H,6-7,10-15H2/t19-,21+,25-,26-,27+/m0/s1

Standard InChI Key:  ZLMLSUIQTYFLKF-XKVUGNILSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 431.53

Molecular Weight (Monoisotopic): 431.2097

AlogP: 2.99

#Rotatable Bonds: 4

Polar Surface Area: 70.00

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.11

CX Basic pKa: 8.90

CX LogP: 3.48

CX LogD: 2.24

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.78

Np Likeness Score: 1.23

References

1. Portoghese PS, Sultana M, Moe ST, Takemori AE..  (1994)  Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.,  37  (5): [PMID:8126697] [10.1021/jm00031a006]

2. Miyata Y, Fujii H, Uenohara Y, Kobayashi S, Takeuchi T, Nagase H..  (2012)  Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant Plasmodium chabaudi.,  22  (16): [PMID:22818080] [10.1016/j.bmcl.2012.06.085]

Source

Source(1):

• Scientific Literature